IRVINGTON, N.Y., Sept. 30, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that Tony Dimun, Chairman of Nascent Enterprises, has been appointed as a Director and a member of the Company's Audit Committee, effective as of October 1, 2013.
Help employers find you! Check out all the jobs and post your resume.
